124 related articles for article (PubMed ID: 22930215)
1. Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats.
Kitta T; Tyagi V; Nanri M; Kiniwa M; Nonomura K; Yoshimura N
Int Urogynecol J; 2013 Apr; 24(4):683-8. PubMed ID: 22930215
[TBL] [Abstract][Full Text] [Related]
2. Propiverine increases urethral wall catecholamine levels and bladder leak point pressure in rats.
Nishijima S; Sugaya K; Kadekawa K; Ashitomi K; Ueda T; Yamamoto H
Int J Urol; 2016 Jan; 23(1):93-9. PubMed ID: 26502799
[TBL] [Abstract][Full Text] [Related]
3. Effect of propiverine hydrochloride on stress urinary incontinence.
Sugaya K; Sekiguchi Y; Satoh T; Shiroma K; Kadekawa K; Ashitomi K; Nishijima S
Int J Urol; 2014 Oct; 21(10):1022-5. PubMed ID: 24930995
[TBL] [Abstract][Full Text] [Related]
4. Excitatory effect of propiverine hydrochloride on urethral activity in rats.
Kadekawa K; Nishijima S; Ashitomi K; Yamamoto H; Sugaya K
Int J Urol; 2012 Jun; 19(6):575-82. PubMed ID: 22376304
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of propiverine hydrochloride on mixed-type urinary incontinence in women: The Female Urgency and Stress Urinary Incontinence Study of Propiverine Hydrochloride trial.
Minagawa T; Gotoh M; Yokoyama O; Sugaya K; Yamanishi T; Kawahara K; Kaga K; Kikuchi T; Nishizawa O;
Int J Urol; 2018 May; 25(5):486-491. PubMed ID: 29651806
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of propiverine, an anticholinergic agent, in young and old rats.
Nishijima S; Sugaya K; Kadekawa K; Ashitomi K; Yamamoto H
Life Sci; 2011 Sep; 89(13-14):456-9. PubMed ID: 21819997
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Usefulness of Propiverine Hydrochloride in Poor Responders to Previous Anticholinergics.
Masumori N; Funato Y; Yamaguchi Y; Itoh K
Low Urin Tract Symptoms; 2018 May; 10(2):116-121. PubMed ID: 29664239
[TBL] [Abstract][Full Text] [Related]
8. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
Yokoyama O; Miwa Y; Oyama N; Aoki Y; Ito H; Akino H
J Urol; 2007 Nov; 178(5):2208-12. PubMed ID: 17870108
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory role of the spinal cholinergic system in the control of urethral continence reflex during sneezing in rats.
Yoshikawa S; Kitta T; Miyazato M; Sumino Y; Yoshimura N
Neurourol Urodyn; 2014 Apr; 33(4):443-8. PubMed ID: 23754327
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.
Siegmund W; Sillén U; Läckgren G; Schnabel F; Mürtz G; Feustel C
Clin Pharmacokinet; 2010 May; 49(5):335-42. PubMed ID: 20384395
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).
Madersbacher H; Mürtz G
World J Urol; 2001 Nov; 19(5):324-35. PubMed ID: 11760781
[TBL] [Abstract][Full Text] [Related]
13. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
Moon HS; Lee JW; Park SY; Son YW; Kim YT
Urology; 2010 Aug; 76(2):509.e8-12. PubMed ID: 20546876
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological evaluation of efficacy and safety of propiverine hydrochloride in patients of overactive bladder--relationship between urodynamic observation and propiverine pharmacokinetics--].
Sugiyama T; Shimizu N; Hashimoto K; Yoshioka N; Hanai T; Matsumoto S; Uemura H
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):670-7. PubMed ID: 16363652
[TBL] [Abstract][Full Text] [Related]
15. Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy-induced oestrogen deficiency.
Kadekawa K; Kawamorita N; Shimizu T; Kurobe M; Turnbull PS; Chandra S; Kambara T; Barton JC; Russell AJ; Yoshimura N
BJU Int; 2020 Jun; 125(6):911-919. PubMed ID: 32011085
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study.
Lee KS; Choo MS; Kim DY; Kim JC; Kim HJ; Min KS; Lee JB; Jeong HJ; Lee T; Park WH
J Urol; 2005 Oct; 174(4 Pt 1):1334-8. PubMed ID: 16145414
[TBL] [Abstract][Full Text] [Related]
17. [Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of detrusor hyperactivity and increased sensitivity and irritability of the urinary bladder: results of a study monitoring drug utilization].
Halaska M; Martan A; Voigt R; Kaplan F; Raus K; Masata J; Klemenc J
Ceska Gynekol; 1997 Oct; 62(5):259-64. PubMed ID: 9600163
[TBL] [Abstract][Full Text] [Related]
18. Effects of propiverine and naftopidil on the urinary ATP level and bladder activity after bladder stimulation in rats.
Sugaya K; Nishijima S; Tasaki S; Kadekawa K; Miyazato M; Ogawa Y
Neurosci Lett; 2007 Dec; 429(2-3):142-6. PubMed ID: 17997223
[TBL] [Abstract][Full Text] [Related]
19. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
[TBL] [Abstract][Full Text] [Related]
20. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
